Pharmacokinetics, Safety, and Efficacy of Acalabrutinib in Chinese Patients with Relapsed/Refractory Mantle Cell Lymphoma and Other B-Cell Malignancies: An Open-Label, Multicenter Phase 1/2 Trial

被引：1
|
作者：
Zhu, Jun [1 ]
Song, Yuqin [1 ]
Li, Jianyong [2 ]
Zhou, Keshu [3 ]
Ke, Xiaoyan [4 ]
Cai, Zhen [5 ]
Zhang, Huilai [6 ]
Yao, Tingting [7 ]
Xia, Zhen [7 ]
Wang, Yiqiu [7 ]
Lai, Peiqiong [7 ]
Liu, Xiaofeng [7 ]
机构：
[1] Peking Univ Canc Hosp & Inst, Dept Lymphoma, Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
[2] Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Peoples R China
[3] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Zhengzhou, Peoples R China
[4] Peking Univ Third Hosp, Dept Hematol, Beijing, Peoples R China
[5] Zhejiang Univ, Affiliated Hosp 1, Med Coll, Dept Hematol, Hangzhou, Peoples R China
[6] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[7] AstraZeneca, Shanghai, Peoples R China
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-157057
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6496 / 6497
页数：2
相关论文
共 50 条
  • [1] Phase 1/2 multicenter trial of acalabrutinib in Chinese patients with relapsed/refractory mantle cell lymphoma
    Song, Yuqin
    Li, Jianyong
    Zhou, Keshu
    Ke, Xiaoyan
    Cai, Zhen
    Zhang, Huilai
    Yao, Tingting
    Xia, Zhen
    Wang, Yiqiu
    Lai, Peiqiong
    Liu, Xiaofeng
    Zhu, Jun
    LEUKEMIA & LYMPHOMA, 2024, 65 (05) : 647 - 652
  • [2] Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study
    Song, Yuqin
    Song, Yongping
    Liu, Lihong
    Zhang, Mingzhi
    Li, Zhiming
    Ji, Chunyan
    Xu, Wei
    Liu, Ting
    Xu, Bing
    Wang, Xin
    Gao, Sujun
    Zhang, Huilai
    Hu, Yu
    Li, Yan
    Cheng, Ying
    Yang, Haiyan
    Cao, Junning
    Zhu, Zunmin
    Hu, Jianda
    Zhang, Wei
    Jing, Hongmei
    Ding, Kaiyang
    Lu, Zhengguang
    Zhang, Bin
    Zhao, Renbin
    Xu, Zhixin
    Zhu, Jun
    BLOOD, 2019, 134
  • [3] Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study
    Song, Yuqin
    Song, Yongping
    Liu, Lihong
    Zhang, Mingzhi
    Li, Zhiming
    Ji, Chunyan
    Xu, Wei
    Liu, Ting
    Xu, Bing
    Wang, Xin
    Gao, Sujun
    Zhang, Huilai
    Hu, Yu
    Li, Yan
    Cheng, Ying
    Yang, Haiyan
    Cao, Junning
    Zhu, Zunmin
    Hu, Jianda
    Zhang, Wei
    Jing, Hongmei
    Ding, Kaiyang
    Lu, Zhengguang
    Zhang, Bin
    Zhao, Renbin
    Xu, Zhixin
    Zhu, Jun
    BLOOD, 2020, 136
  • [4] GLOBRYTE: A Phase III, Open-Label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma
    Phillips, Tycel J.
    Matasar, Matthew
    Eyre, Toby A.
    Gine, Eva
    De L'Etang, Audrey Filezac
    Byrne, Ben
    Lundberg, Linda
    Padovani, Alejandra
    Boetsch, Christophe
    Bottos, Alessia
    Qayum, Naseer
    BLOOD, 2023, 142
  • [5] A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies
    Collins, Graham P.
    Clevenger, Tracy N.
    Burke, Kathleen A.
    Yang, Buyue
    MacDonald, Alex
    Cunningham, David
    Fox, Christopher P.
    Goy, Andre
    Gribben, John
    Nowakowski, Grzegorz S.
    Roschewski, Mark
    Vose, Julie M.
    Vallurupalli, Anusha
    Cheung, Jean
    Raymond, Amelia
    Nuttall, Barrett
    Stetson, Dan
    Dougherty, Brian A.
    Schalkwijk, Stein
    Carnevalli, Larissa S.
    Willis, Brandon
    Tao, Lin
    Harrington, Elizabeth A.
    Hamdy, Ahmed
    Izumi, Raquel
    Pease, J. Elizabeth
    Frigault, Melanie M.
    Flinn, Ian
    LEUKEMIA & LYMPHOMA, 2021, 62 (11) : 2625 - 2636
  • [6] Acalabrutinib in Chinese patients with relapsed/refractory chronic lymphocytic leukemia: Primary analysis from an open-label, multicenter phase 1/2 trial
    Yang, Shenmiao
    Huang, Haiwen
    Zhou, Keshu
    Zhao, Xielan
    Han, Yanqiu
    Li, Lindong
    Wang, Yujie
    Liu, Xiaofeng
    Li, Jianyong
    ANNALS OF HEMATOLOGY, 2024, : 701 - 712
  • [7] Phase 1/2 Trial of Acalabrutinib Plus Pembrolizumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (08) : 9 - 10
  • [8] A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma
    Martin, Peter
    Goy, Andre
    Ramchandren, Radhakrishnan
    Ferrante, Lucille
    Londhe, Anil
    McGowan, Tracy
    Bartlett, Nancy L.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (04) : 1027 - 1030
  • [9] Geptanolimab in Chinese patients with relapsed or refractory primary mediastinal large B-cell lymphoma: Results from a multicenter, open-label, single-arm phase II trial
    Shi, Y-K.
    Cui, J.
    Zhou, H.
    Zhang, X.
    Zou, L. Q.
    Liu, H.
    Zhang, H.
    Li, X.
    Zhang, W.
    Zhou, F.
    Zhong, L.
    Jin, C.
    Zhang, H.
    Peng, Z.
    Gao, Y.
    Cao, J.
    Ma, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S775 - S776
  • [10] Acalabrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): Results of a phase 2, multicenter, open-label trial.
    Budde, L. Elizabeth
    Coleman, Morton
    Stevens, Don A.
    Ma, Shuo
    Patti, Caterina
    Levy, M. Yair
    Lossos, Izidore S.
    Geethakumari, Praveen Ramakrishnan
    Lam, Selay
    Calvo, Roser
    Higgins, Kara
    Strati, Paolo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345